Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.67 |
| ▸ | DRD3 | P35462 | 14/20 | 0.67 |
| ▸ | DRD4 | P21917 | 13/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508893 | 0.94 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AKDM4E | |
| SCHEMBL5507888 | 0.89 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL5510402 | 0.85 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL5505000 | 0.85 | DRD2 (0.64) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL5512907 | 0.83 | DRD2 (0.57) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL5506481 | 0.82 | DRD2 (0.68) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL5506541 | 0.82 | DRD2 (0.66) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL5336144 | 0.81 | HTR7 (0.55) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL5510364 | 0.80 | DRD2 (0.58) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL5502062 | 0.74 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | claimed |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SCHWARZ PHARMA AG (DE) | 2005-09-08 | — | — | US | claimed |
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SCHWARZ PHARMA AG (DE) | 2005-09-08 | — | — | US | disclosed |
| EP-1519726-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004004729-A1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SCHWARZ PHARMA AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197343-A1 | Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases | SLC6A3, DRD2, ADH1A | DRD2 2/4885DRD3 9/4885DRD4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.